HC Wainwright Reiterates Buy Rating on ENGN
HC Wainwright maintains its buy rating on ENGN, setting a $4 target price, a 125.99% upside from the current price.
Key Points
- HC Wainwright reiterated its buy rating on ENGN with a $4 target price on June 16, 2026.
- HC Wainwright's $4 price target implies 125.99% upside from enGene Therapeutics Inc.'s ($ENGN) current $1.77 share price.
- ENGN shares are trading at $1.77, reflecting ongoing interest from analysts and insiders.
- Institutional activity includes significant share changes by Siren, L.L.C. and Blue Owl Capital Holdings LP.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
On June 16, 2026, HC Wainwright reiterated its buy rating on ENGN, setting a target price of $4. Analyst Andres Y. Maldonado expressed a positive outlook for the company, which is currently trading at $1.77 per share.
Other Institutional Activity in ENGN
Several institutional investors have shown varied interest in ENGN. FCPM III Services B.V. held steady with 9,632,561 shares valued at approximately $65.6 million. Perceptive Advisors LLC slightly trimmed its position by 41,570 shares, bringing its total to 5,827,506 shares worth about $39.7 million. Siren, L.L.C. significantly increased its holdings by 1,916,895 shares, now owning 5,253,159 shares valued at $35.8 million. Blue Owl Capital Holdings LP also boosted its stake by 1,055,416 shares, reaching 4,416,353 shares with a value of $30.1 million.
Insider Buying and Selling at enGene Therapeutics Inc.
In a notable insider buying spree on January 30, 2026, several key executives acquired shares at no cost. CEO and President Ronald Harold Wilfred Cooper purchased 801,000 shares, while Chief Technology Officer Joan Connolly, Chief Development Officer Jill Buck, Chief Strategy & Ops Officer Alexander Julian Nichols, and Chief Legal Officer Lee Giguere each acquired 195,000 shares. These transactions were not part of a pre-planned trading program.
Analysts Set New Price Targets
HC Wainwright & Co. maintained its buy rating on ENGN, setting a $4 target on June 16, 2026. Previously, on May 14, 2026, UBS maintained a hold rating with a $2 target. Wells Fargo downgraded the stock to hold on May 8, 2026, also with a $2 target. Meanwhile, Piper Sandler downgraded it to hold with a $4 target on the same day. The analyst consensus suggests a mixed outlook, with a range of ratings from buy to hold.
Bottom Line
HC Wainwright's reiteration of its buy rating on ENGN with a $4 target reflects continued analyst interest. The stock's current trading price and recent insider buying activity suggest potential confidence in the company's future. Institutional investors have also been active, with some increasing their stakes significantly. As always, remember that analyst ratings and institutional filings provide a snapshot of past actions and sentiment, which may not reflect current market conditions.
Get enGene Therapeutics Inc. alerts
New 13F filings, insider trades, and analyst moves on $ENGN, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.